KalVista Pharmaceuticals/$KALV
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About KalVista Pharmaceuticals
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
Ticker
$KALV
Sector
Primary listing
Employees
275
Headquarters
Website
KALV Metrics
BasicAdvanced
$1B
-
-$3.05
-0.40
-
Price and volume
Market cap
$1B
Beta
-0.4
52-week high
$21.31
52-week low
$9.83
Average daily volume
1.1M
Financial strength
Current ratio
5.582
Quick ratio
5.234
Long term debt to equity
-10,355.256
Total debt to equity
-10,483.475
Interest coverage (TTM)
-8.60%
Profitability
EBITDA (TTM)
-164.817
Gross margin (TTM)
25.73%
Net profit margin (TTM)
-223.16%
Operating margin (TTM)
-228.28%
Effective tax rate (TTM)
0.93%
Revenue per employee (TTM)
$270,000
Management effectiveness
Valuation
Price to revenue (TTM)
14.599
Price to book
-374.58
Price to tangible book (TTM)
-374.58
Price to free cash flow (TTM)
-8.579
Free cash flow yield (TTM)
-11.66%
Free cash flow per share (TTM)
-2.326
Growth
Earnings per share change (TTM)
-11.72%
What the Analysts think about KALV
Analyst ratings (Buy, Hold, Sell) for KalVista Pharmaceuticals stock.
KALV Financial Performance
Revenues and expenses
KALV Earnings Performance
Company profitability
KALV News
AllArticlesVideos
KalVista Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference
Business Wire·3 days ago
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·1 week ago
KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data From KONFIDENT-KID Trial of EKTERLY® (sebetralstat) for Children Aged 2-11 Years at the 2026 Global Angioedema Leadership Conference
Business Wire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for KalVista Pharmaceuticals stock?
KalVista Pharmaceuticals (KALV) has a market cap of $1B as of April 11, 2026.
What is the P/E ratio for KalVista Pharmaceuticals stock?
The price to earnings (P/E) ratio for KalVista Pharmaceuticals (KALV) stock is 0 as of April 11, 2026.
Does KalVista Pharmaceuticals stock pay dividends?
No, KalVista Pharmaceuticals (KALV) stock does not pay dividends to its shareholders as of April 11, 2026.
When is the next KalVista Pharmaceuticals dividend payment date?
KalVista Pharmaceuticals (KALV) stock does not pay dividends to its shareholders.
What is the beta indicator for KalVista Pharmaceuticals?
KalVista Pharmaceuticals (KALV) has a beta rating of -0.4. This means that it has an inverse relation to market volatility.